TWI644925B - 可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途 - Google Patents

可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途 Download PDF

Info

Publication number
TWI644925B
TWI644925B TW106143305A TW106143305A TWI644925B TW I644925 B TWI644925 B TW I644925B TW 106143305 A TW106143305 A TW 106143305A TW 106143305 A TW106143305 A TW 106143305A TW I644925 B TWI644925 B TW I644925B
Authority
TW
Taiwan
Prior art keywords
antibody
homo sapiens
dna
antibodies
factor
Prior art date
Application number
TW106143305A
Other languages
English (en)
Chinese (zh)
Other versions
TW201811834A (zh
Inventor
安德莉亞斯 衛爾曼
朱麗亞 施特臘斯堡格
弗蘭克 迪特默
邁克爾 施特雷拉特
安佳 布赫米勒
喬安娜 古魯辛斯卡格貝爾
莉卡達 芬納恩
瑪蒂娜 謝弗爾
克里斯多夫 傑茲
漢娜 喬莉森
板倉亞沙子
梁蘊慧
艾瑞克 塔克
Original Assignee
德商拜耳製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商拜耳製藥股份有限公司 filed Critical 德商拜耳製藥股份有限公司
Publication of TW201811834A publication Critical patent/TW201811834A/zh
Application granted granted Critical
Publication of TWI644925B publication Critical patent/TWI644925B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW106143305A 2012-05-10 2013-05-09 可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途 TWI644925B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
??12167438.6 2012-05-10
EP12167438 2012-05-10
??12181697.9 2012-08-24
EP12181697 2012-08-24
??13150361.7 2013-01-07
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30
US61/817,675 2013-04-30

Publications (2)

Publication Number Publication Date
TW201811834A TW201811834A (zh) 2018-04-01
TWI644925B true TWI644925B (zh) 2018-12-21

Family

ID=49550177

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106143305A TWI644925B (zh) 2012-05-10 2013-05-09 可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途
TW102116466A TWI631140B (zh) 2012-05-10 2013-05-09 可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW102116466A TWI631140B (zh) 2012-05-10 2013-05-09 可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途

Country Status (24)

Country Link
US (4) US9783614B2 (enExample)
EP (2) EP2847228B1 (enExample)
JP (2) JP6348900B2 (enExample)
KR (1) KR102060376B1 (enExample)
CN (1) CN104684932B (enExample)
AR (1) AR091024A1 (enExample)
AU (2) AU2013258043B2 (enExample)
BR (1) BR112014027952B1 (enExample)
CA (1) CA2872926C (enExample)
DK (1) DK2847228T3 (enExample)
ES (1) ES2698950T3 (enExample)
HR (1) HRP20181680T1 (enExample)
HU (1) HUE040580T2 (enExample)
IL (1) IL235238B (enExample)
LT (1) LT2847228T (enExample)
MX (1) MX362454B (enExample)
NZ (1) NZ701121A (enExample)
PL (1) PL2847228T3 (enExample)
RS (1) RS57889B1 (enExample)
SG (2) SG11201406719UA (enExample)
SI (1) SI2847228T1 (enExample)
TW (2) TWI644925B (enExample)
WO (1) WO2013167669A1 (enExample)
ZA (1) ZA201407784B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008326348B2 (en) 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
AU2009335643B2 (en) 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
HRP20170784T8 (hr) 2011-10-14 2018-05-18 Bristol-Myers Squibb Company Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
SI2847228T1 (sl) 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (enExample) 2014-01-31 2018-03-10
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG10201805646WA (en) 2014-08-07 2018-08-30 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3240570B1 (en) 2015-01-02 2025-09-24 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EA201890340A1 (ru) 2015-07-21 2018-09-28 Дайэкс Корп. Моноклональное антитело-ингибитор фактора xiia
EP3325010B1 (en) 2015-07-23 2023-06-21 The Regents of The University of California Antibodies to coagulation factor xia and uses thereof
AR107505A1 (es) * 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
US11059905B2 (en) 2016-03-23 2021-07-13 Prothix B.V. Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
DK3515947T3 (da) * 2016-09-20 2024-07-29 Aronora Inc Hidtil ukendte antistoffer mod faktor XI og anvendelser deraf
EP3535390A4 (en) * 2016-11-02 2020-11-25 Inc. Aronora COMBINATION OF THROMBIN E-WE ANALOGUE AND FIBRINOLYTIC
AU2017383232B2 (en) * 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
BR112019014785A2 (pt) * 2017-01-19 2020-05-12 Bayer Pharma Aktiengesellschaft Nova formulação estável para anticorpos fxia
WO2020029179A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
WO2019102353A1 (en) 2017-11-22 2019-05-31 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP2021529800A (ja) * 2018-07-05 2021-11-04 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ＦＸＩａ抗体のための新規な安定した高濃度製剤
PE20211399A1 (es) * 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
CN120433850A (zh) 2018-08-07 2025-08-05 日本电信电话株式会社 光传输系统和传输模式选择方法
CN113348000A (zh) * 2018-09-17 2021-09-03 德克萨斯大学体系董事会 用于治疗骨损伤的组合物和方法
WO2020089380A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES
EP3914624A4 (en) * 2019-01-21 2022-10-19 Aronora, Inc. NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES
CN113474374B (zh) 2019-04-16 2025-05-02 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TWI882142B (zh) * 2020-07-02 2025-05-01 大陸商北京拓界生物醫藥科技有限公司 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
WO2024141099A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
ES2325045T3 (es) 1996-10-14 2009-08-24 Bayer Healthcare Ag Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20080219998A1 (en) 2001-12-07 2008-09-11 Andras Gruber Anti-Thrombotic Agents
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
EP3018144A1 (en) 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
CA2685015A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
HUE041556T2 (hu) * 2008-06-19 2019-05-28 Prothix Bv XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
CA2844730A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
JP6054967B2 (ja) 2011-09-02 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アネレート化ピリミジンおよびその使用
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof

Also Published As

Publication number Publication date
CA2872926C (en) 2022-07-05
JP2015517305A (ja) 2015-06-22
HRP20181680T1 (hr) 2018-12-14
HK1207091A1 (en) 2016-01-22
US20180112009A1 (en) 2018-04-26
EP2847228A1 (en) 2015-03-18
SI2847228T1 (sl) 2018-11-30
AU2013258043B2 (en) 2017-11-30
EP3404045A1 (en) 2018-11-21
HUE040580T2 (hu) 2019-03-28
MX2014013568A (es) 2014-12-08
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
LT2847228T (lt) 2018-11-12
KR102060376B1 (ko) 2019-12-30
TW201811834A (zh) 2018-04-01
MX362454B (es) 2019-01-18
US20150099298A1 (en) 2015-04-09
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
CN104684932A (zh) 2015-06-03
US20180051093A1 (en) 2018-02-22
BR112014027952A2 (pt) 2019-07-09
EP2847228B1 (en) 2018-07-25
US11046783B2 (en) 2021-06-29
SG10201609322QA (en) 2017-01-27
TW201400504A (zh) 2014-01-01
KR20150008166A (ko) 2015-01-21
US10221247B2 (en) 2019-03-05
WO2013167669A1 (en) 2013-11-14
BR112014027952B1 (pt) 2022-06-21
US9783614B2 (en) 2017-10-10
NZ701121A (en) 2017-06-30
JP2018148920A (ja) 2018-09-27
AU2018200850A1 (en) 2018-02-22
CN104684932B (zh) 2019-03-12
AU2018200850C1 (en) 2020-03-12
PL2847228T3 (pl) 2019-03-29
IL235238B (en) 2019-08-29
AU2018200850B2 (en) 2019-09-19
DK2847228T3 (en) 2018-11-19
CA2872926A1 (en) 2013-11-14
IL235238A0 (en) 2014-12-31
SG11201406719UA (en) 2014-11-27
AU2013258043A1 (en) 2014-11-13
AR091024A1 (es) 2014-12-30
JP6348900B2 (ja) 2018-06-27
ZA201407784B (en) 2019-01-30
ES2698950T3 (es) 2019-02-06

Similar Documents

Publication Publication Date Title
TWI644925B (zh) 可結合至凝血因子ＸＩ及／或其活化型式因子ＸＩａ的抗體及其用途
JP7223069B2 (ja) プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
CN114316061B (zh) 针对血浆激肽释放酶和因子xii的双特异性抗体
US10266607B2 (en) Antibody binding to TFPI and composition comprising the same
RU2758160C2 (ru) Новые антитела против фактора xi и их применения
JP2022523007A (ja) 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用
HK1207091B (zh) 能够结合凝血因子xi和/或其活化形式因子xia的抗体及其用途
TR201815476T4 (tr) Koagülasyon Faktörü XI ve/veya bunun aktive formu faktör XIa'ya bağlanabilen antikorlar ve bunların kullanımları.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees